NasdaqGM:TMDXMedical Equipment
TransMedics Group (TMDX) Is Down 13.0% After ENHANCE Heart IDE Approval And Platform Expansion - Has The Bull Case Changed?
Earlier in 2026, TransMedics Group reported US$727–US$757 million in 2026 revenue guidance, a higher operating margin of 13% in the latest quarter, and secured full FDA IDE approval for its ENHANCE Heart trial as it expands its National OCS Program to nearly 30% of U.S. transplant procedures.
Beyond device sales, TransMedics is moving toward a vertically integrated transplant platform that could become embedded in the federal transplant ecosystem by 2027, potentially reshaping how multiple...